Autopsy report · NCT00356421
A Clinical Trial Comparing Efficacy and Safety of Exubera® and Humalog®
Cause of deathNo reason given
“See termination reason in detailed description.”
Life of this trial
- Registered 4 months before it started.
- Ran for about 1 year 7 months before it stopped.
- 58 participants enrolled.
- Results were posted on the registry 1 year 2 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 4
- Sponsor
- Pfizer
- Sponsor type
- Industry
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Inhaled Human Insulin (Exubera®); Insulin lispro (Humalog)
- Participants
- 58
- Sites
- 23
- Countries
- Austria, Belgium, Denmark, Finland, France, Ireland, Netherlands, Norway, Portugal, Spain, Sweden, United Kingdom and more
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.